A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies

被引:257
作者
Kratz, Johannes R. [1 ]
He, Jianxing [2 ]
Van den Eeden, Stephen K. [3 ]
Zhu, Zhi-Hua [4 ]
Gao, Wen [5 ]
Pham, Patrick T. [1 ]
Mulvihill, Michael S. [1 ]
Ziaei, Fatemeh [6 ]
Zhang, Huanrong [2 ]
Su, Bo
Zhi, Xiuyi [7 ]
Quesenberry, Charles P. [3 ]
Habel, Laurel A. [3 ]
Deng, Qiuhua [2 ]
Wang, Zongfei [2 ]
Zhou, Jiangfen [2 ]
Li, Huiling [2 ]
Huang, Mei-Chun [6 ]
Yeh, Che-Chung [1 ]
Segal, Mark R. [1 ]
Ray, M. Roshni [1 ]
Jones, Kirk D. [1 ]
Raz, Dan J. [1 ]
Xu, Zhidong [1 ]
Jahan, Thierry M. [1 ]
Berryman, David [6 ]
He, Biao [1 ]
Mann, Michael J. [1 ]
Jablons, David M. [1 ]
机构
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Guangzhou Med Univ, Affiliated Hosp 1, State Key Lab Resp Dis, Dept Cardiothorac Surg, Guangzhou, Guangdong, Peoples R China
[3] Kaiser Permanente Dept Res, Oakland, CA USA
[4] Sun Yat Sen Univ, Ctr Canc, Dept Thorac Oncol, Guangzhou 510275, Guangdong, Peoples R China
[5] Shanghai Pulm Hosp, Shanghai, Peoples R China
[6] Pinpoint Genom, Mountain View, CA USA
[7] Capital Med Univ, Beijing Lung Canc Ctr, Beijing, Peoples R China
关键词
GENE-EXPRESSION SIGNATURES; VINORELBINE PLUS CISPLATIN; ADJUVANT CHEMOTHERAPY; RECURRENCE; PROGNOSIS; MORTALITY; MODEL;
D O I
10.1016/S0140-6736(11)61941-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The frequent recurrence of early-stage non-small-cell lung cancer (NSCLC) is generally attributable to metastatic disease undetected at complete resection. Management of such patients depends on prognostic staging to identify the individuals most likely to have occult disease. We aimed to develop and validate a practical, reliable assay that improves risk stratification compared with conventional staging. Methods A 14-gene expression assay that uses quantitative PCR, runs on formalin-fixed paraffin-embedded tissue samples, and differentiates patients with heterogeneous statistical prognoses was developed in a cohort of 361 patients with non-squamous NSCLC resected at the University of California, San Francisco. The assay was then independently validated by the Kaiser Permanente Division of Research in a masked cohort of 433 patients with stage I non-squamous NSCLC resected at Kaiser Permanente Northern California hospitals, and on a cohort of 1006 patients with stage I-III non-squamous NSCLC resected in several leading Chinese cancer centres that are part of the China Clinical Trials Consortium (CCTC). Findings Kaplan-Meier analysis of the Kaiser validation cohort showed 5 year overall survival of 71.4% (95% CI 60.5-80.0) in low-risk, 58.3% (48.9-66.6) in intermediate-risk, and 49.2% (42.2-55.8) in high-risk patients (p(trend)=0.0003). Similar analysis of the CCTC cohort indicated 5 year overall survivals of 74.1% (66.0-80.6) in low-risk, 57.4% (48.3-65.5) in intermediate-risk, and 44.6% (40.2-48.9) in high-risk patients (p(trend)<0.0001). Multivariate analysis in both cohorts indicated that no standard clinical risk factors could account for, or provide, the prognostic information derived from tumour gene expression. The assay improved prognostic accuracy beyond National Comprehensive Cancer Network criteria for stage I high-risk tumours (p<0.0001), and differentiated low-risk, intermediate-risk, and high-risk patients within all disease stages. Interpretation Our practical, quantitative-PCR-based assay reliably identified patients with early-stage non-squamous NSCLC at high risk for mortality after surgical resection.
引用
收藏
页码:823 / 832
页数:10
相关论文
共 44 条
[1]   Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: Initial results of the randomized, prospective ACOSOG Z0030 trial [J].
Allen, MS ;
Darling, GE ;
Pechet, TTV ;
Mitchell, JD ;
Herndon, JE ;
Landreneau, RJ ;
Inculet, RI ;
Jones, DR ;
Meyers, BF ;
Harpole, DH ;
Putnam, JB ;
Rusch, VW .
ANNALS OF THORACIC SURGERY, 2006, 81 (03) :1013-1019
[2]  
[Anonymous], 2011, NCCN clinical practice guidelines in Oncology breast cancer
[3]  
[Anonymous], STUD TARC SURG ADJ C
[4]  
[Anonymous], FIL SSDM
[5]  
[Anonymous], 2011, LANG ENV STAT COMP
[6]   Long-Term Results of the International Adjuvant Lung Cancer Trial Evaluating Adjuvant Cisplatin-Based Chemotherapy in Resected Lung Cancer [J].
Arriagada, Rodrigo ;
Dunant, Ariane ;
Pignon, Jean-Pierre ;
Bergman, Bengt ;
Chabowski, Mariusz ;
Grunenwald, Dominique ;
Kozlowski, Miroslaw ;
Le Pechoux, Cecile ;
Pirker, Robert ;
Pinel, Maria-Izabel Sathler ;
Tarayre, Michele ;
Le Chevalier, Thierry .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) :35-42
[7]   Gene Profiling of Clinical Routine Biopsies and Prediction of Survival in Non-Small Cell Lung Cancer [J].
Baty, Florent ;
Facompre, Michael ;
Kaiser, Sergio ;
Schumacher, Martin ;
Pless, Miklos ;
Bubenclorf, Lukas ;
Savic, Spasenija ;
Marrer, Estelle ;
Budach, Wolfgang ;
Buess, Martin ;
Kehren, Jeanne ;
Tamm, Michael ;
Brutsche, Martin H. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181 (02) :181-188
[8]   Gene-expression profiles predict survival of patients with lung adenocarcinoma [J].
Beer, DG ;
Kardia, SLR ;
Huang, CC ;
Giordano, TJ ;
Levin, AM ;
Misek, DE ;
Lin, L ;
Chen, GA ;
Gharib, TG ;
Thomas, DG ;
Lizyness, ML ;
Kuick, R ;
Hayasaka, S ;
Taylor, JMG ;
Iannettoni, MD ;
Orringer, MB ;
Hanash, S .
NATURE MEDICINE, 2002, 8 (08) :816-824
[9]  
Black WC, 2002, JNCI-J NATL CANCER I, V94, P167, DOI 10.1093/jnci/94.3.167
[10]   Prognostic gene signatures for non-small-cell lung cancer [J].
Boutros, Paul C. ;
Lau, Suzanne K. ;
Pintilie, Melania ;
Liu, Ni ;
Shepherd, Frances A. ;
Der, Sandy D. ;
Tsao, Ming-Sound ;
Penn, Linda Z. ;
Jurisica, Igor .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (08) :2824-2828